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Abstract: 
Background: Cerebral venous sinus thrombosis (CVST) refers to a distinct stroke type accounting for 0.5% to 1% 
of all strokes. Standard treatment for CVST with warfarin is limited by the need for continuous monitoring of 
anticoagulation with INR. A simple solution to some of these issues could be administration of an oral anticoagulant 
that does not require laboratory monitoring yet is effective as a single agent for the treatment of acute venous 
thromboembolism and for continued treatment. Rivaroxaban is one such medicine that can solve this problem.  
Methodology:  It was an open label interventional clinical quasi-controlled Trial conducted at Department of 
Neurology, Sir Ganga Ram Hospital/Fatima Jinnah Medical University, Lahore for duration of 20 months from 
January, 2017 to August, 2018. Patients were randomly divided into two groups (Group Warfarin, and Group 
Rivaroxaban) using computer generated random number table. Treatment started with low molecular weight 
heparin (Enoxaparin 1mg/kg body weight/day) for 5 to 7 days depending upon improvement in neurological status.  
Group Rivaroxaban was given Rivaroxaban 15mg twice a day for 21 days followed by 20 mg daily for 12 weeks. 
Group Warfarin was given warfarin starting with a dose of 5mg and titrating to a target INR 2.0 to 3.0. Patients 
were followed over 6 months. 
Results: Overall 30 patients were included in the study. Group Warfarin includes 15 patients and group 
rivaroxaban also includes 15 patients. Detailed characteristics of all patients in both groups have been summarized 
in table I.  
Female patients were 11 (73.33% in group warfarin and 10 (66.66%) in group rivaroxaban. 
Overall, warfarin and rivaroxaban both showed efficacy in treatment of cerebral venous sinus thrombosis without 
any significant difference betweem two groups (P-Value= 0.543). Table II. Overall efficacy was upto 90%.  
Conclusion: In sum, this study demonstrates that rivaroxaban is effective in managing CVST similar to warfarin. 
Rivaroxaban can be preferred treatment option owing to its safety as no monitoring is needed. Warfarin if 
monitored adequately and INR maintained within target range can be equally safe in this regard. 
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INTRODUCTION: 
Cerebral venous sinus thrombosis (CVST) refers to a 
distinct stroke type accounting for 0.5% to 1% of all 
strokes.[1,2] The clinical spectrum of CVST ranges 
from non-specific or mild symptoms of headache, 
visual complains, focal neurologic deficits, seizures 
or coma. Cerebral venous thrombosis (CVT) affects 
approximately 15 people per million annually and 
represents 0.5% of all stroke. [3,4]. The current 
guidelines recommend initiation of treatment with 
heparin followed by oral anticoagulants with Vitamin 
K antagonists namely warfarin for 3 to 6 months after 
confirmation of diagnosis with computed tomography 
(CT) or magnetic resonance (MR) venography. [5] 
New oral anticoagulants (NOACs) that inhibit factor 
Xa or thrombin directly have been developed. 
Rivaroxaban has been approved as therapy for 
treatment of deep vein thrombosis(DVT) and 
prevention of systemic embolism in patients with 
atrial fibrillation since December, 2011. [6]. The 
EINSTEIN studies and Einstein-Extension showed a 
noninferior efficacy for rivaroxaban compared with 
enoxaparin plus a vitamin K antagonist in patients 
with peripheral deep vein thrombosis [8,9] In 
ROCKET AF trial, rivaroxaban was noninferior to 
warfarin for the prevention of stroke or systemic 
embolism in patients with atrial firillation. [1] 
 
Apixaban and rivaroxaban have been shown to be 
non-inferior to warfarin for the treatment of deep 
vein thrombosis and pulmonary embolism. [10,11]. 
However, only case reports and small case series 
have described their use in patients with cerebral 
venous sinus thrombosis. Standard treatment for 
CVST with warfarin is limited by the need for 
continuous monitoring of anticoagulation with INR. 
This presents a challenge to outpatient 
management since treatment with a vitamin K 
antagonist requires laboratory monitoring and dose 
adjustment and may be complicated by drug and food 
interactions. After the first year, the annual risk of 
major bleeding associated with vitamin K antagonists 
is 1 to 2%. [18] Consequently, the balance between 
the risks and the benefits of continued therapy 
remains a subject of debate, despite the high long-
term risk of recurrent venous thromboembolism. A 
simple solution to some of these issues could be 
administration of an oral anticoagulant that does not 
require laboratory monitoring yet is effective as a 
single agent for the treatment of acute venous 
thromboembolism and for continued treatment.12 
Rivaroxaban is one such medicine that can solve this 
problem. The current study has been conducted to 
compare the efficacy of these two medicines to make 
recommendations for treatment of CVST with a 
reliably safe medicine like rivaroxaban. 
 
MATERIALS & METHODS: 
It was an open label interventional clinical quasi-
controlled Trial conducted at Department of 
Neurology, Sir Ganga Ram Hospital/Fatima Jinnah 
Medical University, Lahore for duration of 20 
months from January, 2017 to August, 2018. Total 30 
patients were enrolled in the study. Sampling 
Technique was non-probability consecutive 
sampling.  Patients of both genders with ages 
between 14 and 70 years having cerebral venous 
sinus thrombosis (Patients with headache, new onset 
neurological deficit or seizures having evidence of 
cerebral venous thrombosis on magnetic resonance 
venography) were included in the study. Patient 
anticipated to require invasive procedure (e.g., 
lumbar puncture, thrombectomy, hemicraniectomy) 
prior to initiation of oral anticoagulation, Impaired 
renal function (Creatinine clearance < 30 mL/min), 
Pregnancy, Lactating mother, Bleeding diathesis or 
other contraindication to anticoagulation, Any 
concurrent medical condition requiring mandatory 
antiplatelet or anticoagulant use, Concomitant use of 
strong CYP3A4 inducers (e.g., ongoing use of 
dilantin, carbamazepine, HIV protease inhibitors) or 
CYP3A4 inhibitors (e.g., diltiazem, systemic 
ketoconazole), severe or fatal comorbid illness that 
will prevent improvement, or cannot complete follow 
up were excluded from the study. Informed consent 
was taken from each participant of the study. Patients 
were randomly divided into two groups (Group 
Warfarin, and Group Rivaroxaban) using computer 
generated random number table. Treatment started 
with low molecular weight heparin (Enoxaparin 
1mg/kg body weight/day) for 5 to 7 days depending 
upon improvement in neurological status.  Group 
Rivaroxaban was given Rivaroxaban 15mg twice a 
day for 21 days followed by 20 mg daily for 12 
weeks. Group Warfarin was given warfarin starting 
with a dose of 5mg and titrating to a target INR 2.0 to 
3.0. Patients were followed over 6 months. 
 
Primary outcome measure was recanalization at 24 
weeks on MRV (no recanalization, partial 
recanalization, complete recanalization). Secondary 
outcome measure was achievement of modified 
Rankin Scale 0-1 (Annex I).  
 
Patients were followed for bleeding events over 6 
months. Symptomatic intracranial bleeding during 6 
months, Major extracranial bleeding (bleeding in a 
critical area or organ, including intraspinal, 
intraocular, retroperitoneal, intra-articular or 
pericardial, or intramuscular with compartment 
syndrome, and/or bleeding causing a drop in 
hemoglobin by 20 g/L or more, leading to transfusion 
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of 2 or more units of whole blood or red cells) at 6 
months, Clinically relevant non-major 
bleeding(Epistaxis, mucosal bleed, conjunctival 
hemorrhage, heavy menstrual bleeding, ecchymosis) 
during 6 months. 
 
Data was collected using a standardized Performa by 
investigators. All the collected information was 
transferred to SPSS version 20 and analyzed. Mean 
and standard deviation were calculated for all 
quantitative variables like age and modified rankin 
scale. Frequency and percentages were calculated for 
all qualitative variables like gender, recanalization at 
6 months, symptomatic intracranial bleeding during 6 
months, major extra cranial bleeding, clinically 
relevant non major bleeding during 6 months. 
Efficacy was defined as modified Rankin scale of 0-
1. Efficacy was compared in both groups using chi 
square test. P value of <0.05 was taken as significant. 
Independent sample t test was applied to see efficacy 
of treatment in group A and group B. P value of 
<0.05 was taken as significant. 
 
RESULTS:  
Overall 30 patients were included in the study. Group 
Warfarin includes 15 patients and group rivaroxaban 
also includes 15 patients. Detailed characteristics of 
all patients in both groups have been summarized in 
table I.  
Female patients were 11 (73.33% in group warfarin 
and 10 (66.66%) in group rivaroxaban. 
 
Overall, warfarin and rivaroxaban both showed 
efficacy in treatment of cerebral venous sinus 
thrombosis without any significant difference 
betweem two groups (P-Value= 0.543). Table II. 
Overall efficacy was upto 90%.  
 
Table I: Characteristics of the Study Population 
 
 Group warfarin 
n = 15 
Group rivaroxaban 
n = 15 
P-Value 
Age 35.87+10.789 31.47+9.187 0.249 
Gender  
Male 
4 (26.6%) 5 (33.3%) 
0.690 
Female 
11 (73.33%) 10(66.66%) 
Modified Rankin Scale at 
presentation 
3.73+0.799 3.47+0.743 0.649 
Modified Rankin Scale at 
Follow up 
0.40+0.83 0.47+1.06 0.505 
Complete Recanalization 8 (53.33%) 6 (40%) 
0.706 
Partial Recanalization 6(405) 7 (46.67%) 
No Recanalization 1(6.67%) 2(13.33%) 
Major Extracranial 
Bleeding 
0 0 
 
 
Major Extracranial 
Bleeding 
0 0 
 
Minor extracranial 
bleeding 
1(6.67%) 3 (205) 
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Table II: Comparison of Efficacy in the both groups 
 
 Efficacy Total 
Yes No 
Group 
Warfarin 14 (93.335) 1 (6.675%) 15 
Rivaroxaban 13 (86.66%) 2 (13.335) 15 
Total 27 (90%) 3 (10%) 30 (100%) 
Chi square test 0.370   
p-Value 0.543   
 
DISCUSSION: 
Cerebral venous sinus thrombosis is life-threatening 
condition though uncommon with an incidence of 2 
to 5 /million/year although it is variable between 
different studies.13 the standard of care in routine is 
initiation of treatment with heparin (both low 
molecular weight heparin and unfractionated heparin 
can be used) followed by warfarin with a target INR 
of 2.0 to 3.0.14 when there is resistance to treatment, 
endovascular interventional treatmen is also helpful. 
[15]  
 
Rivaroxaban, an orally active, direct factor Xa 
inhibitor, is effective in the prevention and treatment 
of venous thromboembolism. It does not require 
laboratory monitoring and has no food interactions 
and only a few drug interactions., [16,17,18] 
 
Current treatment i.e., heparin followed by warfarin 
for CVST is limited by the need for laboratory 
monitoring and dose adjustment and may be 
complicated by drug and food interactions. Annual 
risk of major bleeding associated with vitamin K 
antagonists is 1 to 2%.  A simple solution to some of 
these issues could be administration of an oral 
anticoagulant that does not require laboratory 
monitoring yet is effective as a single agent for the 
treatment of acute venous thromboembolism and for 
continued treatment. [12] 
 
This was a small scale study including only 30 
patients of cerebral venous sinus thrombosis 
conducted in Neurology ward. The study concluded 
that warfarin and rivaroxaban both are very effective 
in treating cerebral venous sinus thrombosis and 
rivaroxaban is no inferior to warfarin for treatment of 
cerebral venous sinus thrombosis. 
 
In previous epidemiological studies, incidence of cvst 
is higher in females than males. In a systemic review, 
the ratio of Female to male was 2.79 in cvst. It is 
similar to our sstudy in which female population is 
more than two times than male population. [19] 
 
There are very few studies comparing warfarin and 
rivaroxaban. One such study found that both drugs 
are equally effective in treating cerebral venous sinus 
thrombosis. Overall efficacy was upto 90%. 
Complete recanalization was upto 50% with partial 
recanalization also 50%. These results also support 
our study which also concluded that rivaroxaban is 
noninferior to warfarin in treatment of CVST and 
complete recanalization was 53.33% in group 
warfarin and 40% in group rivaroxaban with no 
significant difference. [20] 
 
A study conducted by Anticolli S etal., showed that 
rivaroxaban is effective in treatment of CVST and at 
three months, an excellent outcome (mRS of 0 to 1) 
was observed in 100% of patients and complete or 
partial recanalization in 83%. At 12 months, an 
excellent outcome was observed in 100% of patients 
and complete (33%) or partial recanalization (67%) 
in all cases. There were no bleeding complications 
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(major, clinically relevant nonmajor, or minor) or 
recurrent thrombotic events during followup and all 
patients were alive at last study visit. These results 
also support the results of our study which showed no 
major bleeding and only 1 minor bleeding in group 
warfarin and 3 in group rivaroxaban. [21] 
 
Warfarin is a time tested drug for treatment of CVST 
and it is very cost effective. It needs continuous 
monitoring with PT-INR and if monitoring is not 
done there is always a risk of major intracranial and 
extracranial haemorrhage. Rivaroxaban is a novel 
oral anticoagulant with activity against activated 
Factor X and needs no monitoring. Hence it is an 
asset for the patients and doctors. It is more costly 
than warfarin. 
 
Keeping in view, the small sample size of the study 
and the scarcity of data on the subject especially with 
rivaroxaban, large scale randomized controlled 
studies are needed to convincingly establish and 
compare the efficacy of these medications. 
 
CONCLUSION: 
In sum, this study demonstrates that rivaroxaban is 
effective in managing CVST similar to warfarin. 
Rivaroxaban can be preferred treatment option owing 
to its safety as no monitoring is needed. Warfarin if 
monitored adequately and INR maintained within 
target range can be equally safe in this regard. 
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